Tanya is a registered dietitian, CEO, and founder of MyNutriWeb and Nutrilicious Communications. With 30+ years of experience across healthcare, education, food systems and communications.  She supports professionals and workers within these systems to help people eat well, with a triple win for health, planet and the economy. She is current Chair of the British Dietetic Association’s Sustainable Diets Group and member of the BDA Food Strategy Woking Group, supporting members to embed sustainability into practice through training, guidance and policy change. Tanya believes that the trusted role of healthcare and food professionals by the public, working across multiple sectors in society, position them as powerful agents of change; whose understanding of the key issues and ability to apply change is vital to delivering on some of most pressing health and environmental goals of our time.

Lucy is the chief clinical officer for Oviva; the largest provider of digitally-enabled and reimbursed behaviour change services across Europe. She has been a dietitian for 19 years, working across clinical practice, media, brand consultancy and as a leader in digital healthcare.

This session will be going through the data regarding the safety and efficacy of currently available and new OMMs, then discussing the effects of the medications on hard outcomes (e.g. heart disease, fatty liver disease) and finally ways of practically delivering pharmacotherapy care (e.g. how to manage side effects, exclusion criteria).

Watch this session to:

GAIN CLEAR UNDERSTANDING OF:

• The current, new and pipeline drugs for obesity
• Efficacy, safety, impact of hard outcomes and cost-effectiveness
• Unmet needs in obesity pharmacotherapy
• Use of pharmacotherapy in the NHS

BE AWARE OF:

• Indications for medication in the public and private sector

• Effect of the drugs on weight loss and end-organ damage

• Common and rare side effects

BE ABLE TO:

• Explain the mechanism of action of the drugs to a patient

• Explain possible side effects and how to deal with them

• Define the role of the dietitian in the pharmacotherapy pathway

Nichola is a UK Registered Dietitian with over 17 years of experience working in both the NHS and private sectors. She was recently named Media Spokesperson of the Year by the British Dietetic Association for her work on TV and in print media and is the author of the best-selling book How Not to Eat Ultra-Processed. Follow her online @nicsnutrition.

With the rapid rise in the use of weight loss medications such as GLP-1 receptor agonists, there is an increasing need for tailored, evidence-based nutrition guidance to support both effectiveness and long-term health. This session will explore how dietitians and healthcare professionals can optimise nutritional intake, preserve lean mass, and manage common side effects such as reduced appetite, nausea, and gastrointestinal changes.

Attendees will gain practical, real-world strategies to support patients in achieving sustainable outcomes beyond medication alone, with a focus on behaviour change, nutrient density, and long-term weight maintenance. This talk will be particularly valuable for clinicians looking to stay ahead of emerging trends and deliver safe, patient-centred care in this rapidly evolving area.

Watch this session to:

GAIN CLEAR UNDERSTANDING OF:

• The mechanisms of action of common weight loss medications and their impact on appetite, metabolism, and nutritional intake
• The nutritional risks associated with reduced energy intake, including micronutrient deficiencies and muscle loss
• The role of diet in enhancing medication efficacy and supporting long-term weight management

BE AWARE OF:

• Common side effects (e.g. nausea, constipation, reduced appetite) and their implications for dietary intake
• At-risk groups (e.g. bariatric patients, older adults) who may require additional nutritional monitoring
• Potential pitfalls of relying solely on medication without lifestyle and behavioural support

BE ABLE TO:

• Provide practical, evidence-based dietary advice to patients using weight loss medications
• Support patients in meeting protein, fibre, and micronutrient needs despite reduced appetite
• Develop sustainable nutrition strategies to support weight maintenance after medication use

Louise is a Registered Dietitian in the UK and Australia, specialising in obesity and weight management. She has worked globally, leading clinical teams and developing nutrition programmes across digital health and private practice, with a focus on translating evidence-based science into practical, patient-centred care, including support for individuals using weight loss medications.

The rapid rise in GLP-1 weight loss medications has transformed obesity care, but it has also introduced new clinical risks, ethical considerations, and gaps in patient support.

This session will explore how healthcare professionals can safely and effectively support patients using these medications, with a strong focus on monitoring, risk identification, and escalation pathways.

Attendees will gain practical, real-world guidance on navigating complex cases, ensuring patient safety, and working within professional scope in an evolving treatment landscape.

Watch this session to:

GAIN CLEAR UNDERSTANDING OF:

• Key safety considerations when supporting patients on GLP-1 medications
• What to monitor (clinical, nutritional, and behavioural markers) and appropriate frequency
• The role of the dietitian within a multidisciplinary model of obesity care

BE AWARE OF:

• Red flags indicating increased clinical risk (e.g. rapid weight loss, low intake, disordered eating patterns)
• Situations where medication use may be inappropriate or require escalation
• Safeguarding, ethical considerations and scope of practice boundarie

BE ABLE TO:

• Identify higher-risk patients and implement appropriate monitoring strategies
• Recognise when nutrition support alone is insufficient and escalate appropriately
• Apply clear documentation and decision-making processes to support safe, accountable practice

Dr Nikita Rowley is a researcher specialising in behaviour change, physical activity, and preventative health, with a particular focus more recently on obesity management. Her work explores how healthcare systems can support sustainable lifestyle changes through physical activity pathways, and she is increasingly investigating how behaviour change strategies can optimise outcomes for patients GLP-1s.

GLP-1 receptor agonists are transforming obesity management, but medication alone does not address the complex behavioural, psychological, and environmental drivers of weight gain. Without effective behaviour change support, patients may struggle with adherence, expectations, side effects, and long-term weight maintenance, beyond the injection.

This session will explore how evidence-based behaviour change and communication strategies can optimise outcomes for patients taking weight-loss medications. It will focus on practical approaches clinicians can use to support sustainable habits long term, manage patient expectations, and enhance engagement in real-world settings.

Attendees will gain insight into how to integrate behavioural science into routine care to ensure that pharmacological advances translate into meaningful, lasting health improvements.

Watch this session to:

GAIN CLEAR UNDERSTANDING OF:

• The role of behaviour change in mediating the effectiveness of GLP-1s and other weight-loss medications
• Key behavioural and psychological challenges experienced by patients using pharmacotherapy for weight management
• Evidence-based behaviour change frameworks (e.g. COM-B) relevant to supporting patients in this context

BE AWARE OF:

• Common mismatches between patient expectations and clinical realities of weight-loss medications
• Risks of weight regain and behavioural disengagement without structured support
• The influence of communication style on adherence, motivation, and patient outcomes

BE ABLE TO:

• Apply practical communication strategies to support behaviour change alongside pharmacotherapy
• Identify opportunities to embed behaviour change into routine consultations and care pathways
• Support patients in developing sustainable habits for long-term weight management beyond medication use

Michelle, 58, from Bristol, joined Oviva’s Tier 3 Weight Management Programme in March 2025 after severe arthritis, a lung condition, and her weight left her barely able to walk or leave the house. A year on, she has lost 6 stone and reversed her pre-diabetes. Using Wegovy alongside the Oviva app, she learned to manage side effects, track her food, and check in with health coaches. The results go far beyond the scales, her arthritis symptoms have eased, her mental health has improved dramatically, and she can now enjoy walks and socialise with her family again. 

This session brings the patient perspective to life through a live interview with Michelle, led by dietitian Lucy Jones. Together, they will explore the realities of taking weight-loss medication in practice, including expectations, challenges, side effect management and the wider impact on health and day-to-day life.

Angela is a registered dietitian with 6 years’ experience working in the NHS and private practice, specialising in weight management and type 2 diabetes. She is a supplementary non-medical prescriber leading on the development of obesity medicines clinical pathways in her NHS role. She is also the Scotland representative for the BDA Obesity Specialist Group.

This session will provide an evidence-based overview of how to maintain weight loss in people on obesity medications, addressing gaps in UK guidance, behaviour change strategies and practical approaches informed by emerging evidence.

Watch this session to:

GAIN CLEAR UNDERSTANDING OF:

• Obesity as a chronic condition requiring long-term management
• Evidence for weight regain after stopping GLP-1 therapies.
• Practical maintenance strategies (dose adjustment, step-down, lifestyle)

BE AWARE OF:

• Gaps and uncertainties in current long-term prescribing guidance
• The importance of behaviour change interventions
• Risks of weight regain and lean mass loss post-treatment

BE ABLE TO:

• Individualise long-term maintenance plans
• Communicate realistic expectations and prevention of weight regain
• Make informed clinical decisions despite limited guidance

Giles Yeo is a Professor of Molecular Neuroendocrinology and programme leader at the MRC Metabolic Diseases Unit in Cambridge and his research currently focuses on the influence of genes on feeding behaviour & body-weight. He is a fellow of Wolfson College, and Honorary President of the British Dietetic Association.

The use of Incretin based medications for the treatment obesity is increasing rapidly worldwide. Are they, however, a panacea? In this talk, we will explore their history, their science, and their broader societal impact, and discuss what weight-loss medications mean for the future of obesity care.

Watch this session to:

GAIN CLEAR UNDERSTANDING OF:

• The history of incretin-based therapies within the wider context of obesity treatment
• How incretin-based therapies work and how they fit alongside other approaches to obesity care
• The common side-effects of these drugs and their implications in real-world settings

BE AWARE OF:

• The difference between drug specific side-effects and those that are the result of rapid weight loss
• The common questions from non-experts regarding the use of these drugs, and how to respond to them
• The role of weight loss drugs along side public health approaches to tackling obesity

BE ABLE TO:

• Communicate better about the science surround weight loss drugs
• Critically discuss the role of incretin-based therapies within a wider, whole-system approach to obesity care
• Recognise how weight-loss medications are shaping the future of obesity care and apply this understanding in practice